Idec Pharmaceuticals Corp. has raised $45 million in an initialpublic offering of 3 million shares priced at $15 per share.

The La Jolla, Calif., developer of monoclonal antibody-baseddrugs increased its offering by 500,000 shares from thepreliminary prospectus, and sold the shares at the high end ofits $13 to $15 price range. After the offering, Idec has 8.4million shares outstanding.

Idec has four products in clinical trials. Specifid, its mostadvanced drug, is in Phase III trials to treat B-cell lymphoma.

Underwriters Montgomery Securities, Alex. Brown & Sons Inc.and Lehman Brothers have an option to purchase 450,000shares to cover overallotments.

Idec stock (NASDAQ:IDPH) closed Tuesday at $18.50.

(c) 1997 American Health Consultants. All rights reserved.